# Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects

> **NCT02947334** · PHASE3 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Primary Hyperlipidemia or Mixed Dyslipidemia

## Interventions

- **BIOLOGICAL:** Bococizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02947334
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-10-31
- **Primary completion:** 2019-05-03
- **Final completion:** 2019-05-03
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02947334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02947334, "Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02947334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*